window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Broken String Biosciences

  • Advanced Therapies,Drug Discovery & Development,Genomics and sequencing

    Broken String Biosciences launches BaseMap ABE for genome-wide off-target analysis

    Broken String Biosciences has launched BaseMap ABE, a platform designed [...]

    August 10, 2026
  • Advanced Therapies,Therapeutic Areas

    Broken String renews NIST gene editing safety push with INDUCE-seq technology

    Broken String Biosciences has reaffirmed its commitment to supporting the [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Broken String and BioLizard partner on AI tool to improve gene editing safety

    Eurostars-3 grant supports development of SafeGuide to reduce time and [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CN Bio wins Innovate UK grant to develop human-relevant drug testing workflow
    Categories: Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Research & Development
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top